Background: On March 11, 2011, the Tohoku-Pacific Ocean earthquake (magnitude 9.0) struck the eastern part of Japan. Despite being far from the epicenter of the catastrophic earthquake, the effects were strongly felt in Tokyo, and the aftershocks continued for several months. There are no reports regarding the influence of earthquakes on migraine medication. The aim of our study was to determine the impact of earthquakes on prophylactic therapy with lomerizine in patients with migraine in Tokyo. Methods: The study included patients with migraine who were admitted to outpatient clinics in Tokyo between January 2010 and July 2010 or between January 2011 and July 2011 and who were prescribed lomerizine prophylactically for headache by specialists. We investigated clinical factors from the medical records for 26 of these patients. Results: The study population included 10 patients in 2010 and 16 patients in 2011. The frequency of headaches was reduced to under 5 days/month during February in both the groups. Compared to 2010, the frequency of headaches significantly increased in 2011 in March, April and May. Conclusion: Patients with migraine were sensitive to exposure to the earthquake and their headaches worsened despite successful prophylactic treatment with lomerizine before the Tohoku-Pacific Ocean earthquake.

Keywords:
Migraine, Lomerizine, Headache, Earthquake
1.
Kazama M, Noda T: Damage statistics (summary of the 2011 off the Pacific coast of Tohoku Earthquake damage). Soils Foundations 2012;52:780-792.
2.
National Police Agency, 2011: The 2011 of the Pacific Coast of Tohoku Earthquake Damage Status and Measures by the Police, Public Information Document. http://www.npa.go.jp/archive/keibi/biki/higaijokyo.pdf (in Japanese).
3.
Sakai F, Igarashi H: Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 1997;17:15-22.
4.
Takeshima T, Ishizaki K, Fukuhara Y, Ijiri T, Kusumi M, Wakutani Y, Mori M, Kawashima M, Kowa H, Adachi Y, Urakami K, Nakashima K: Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache 2004;44:8-19.
5.
Ishii M, Shimizu S, Sakairi Y, Nagamine A, Naito Y, Hosaka Y, Naito Y, Kurihara T, Onaya T, Oyamada H, Imagawa A, Shida K, Takahashi J, Oguchi K, Masuda Y, Hara H, Usami S, Kiuchi Y: MAOA, MTHFR, and TNF-β genes polymorphisms and personality traits in the pathogenesis of migraine. Mol Cell Biochem 2012;363:357-366.
6.
Wacogne C, Lacoste JP, Guillibert E, Hugues FC, Le Jeunne C: Stress, anxiety, depression and migraine. Cephalalgia 2003;23:451-455.
7.
Matsumori Y, Fujiwara S: Influence of Tohoku-Pacific Ocean earthquake on headache cases in the affected area. J Headache Pain 2013;1(suppl 1):P22.
8.
Ishii M, Sakairi Y, Hara H, Imagawa A, Shimizu S, Takahashi J, Nagamine A, Naito Y, Masuda Y, Usami S, Kiuchi Y: Negative predictors of clinical response to triptans in patients with migraine. Neurol Sci 2012;33:453-461.
9.
Hara H, Morita T, Sukamoto T, Cutrer FM: Lomerizine (KB-2796), a new antimigraine drug. CNS Drug Rev 1995;1:204-226.
10.
Kanazawa T, Morita T, Harada K, Iwamoto T, Ohtaka H, Sukamoto T, Ito K, Nurimoto S: Selective effect of KB-2796, a new calcium entry blocker, on cerebral circulation: a comparative study of the effects of calcium entry blockers on cerebral and peripheral arterial blood flows. J Cardiovasc Pharmacol 1990;16:430-437.
11.
Yoshidomi M, Hayashi T, Abe K, Kogure K: Effects of a new calcium channel blocker, KB-2796, on protein synthesis of the CA1 pyramidal cell and delayed neuronal death following transient forebrain ischemia. J Neurochem 1989;53:1589-1594.
12.
Hara H, Ozaki A, Yoshidomi M, Sukamoto T: Protective effect of KB-2796, a new calcium antagonist, in cerebral hypoxia and ischemia. Arch Int Pharmacodyn 1990;304:206-218.
13.
Hara H, Harada K, Sukamoto T: Chronological atrophy after transient middle cerebral artery occlusion in rats. Brain Res 1993;618:251-260.
14.
Shimazawa M, Hara H, Watano T, Sukamoto T: Effects of Ca2+ channel blockers on cortical hypoperfusion and expression of c-Fos-like immunoreactivity after cortical spreading depression in rats. Br J Pharmacol 1995;115:1359-1368.
15.
Lucetti C, Nuti A, Pavese N, Gambaccini G, Rossi G, Bonuccelli U: Flunarizine in migraine prophylaxis: predictive factors for a positive response. Cephalalgia 1998;18:349-352.
16.
Galletti F, Cupini LM, Corbelli I, Calabresi P, Sarchielli P: Pathophysiology basis of migraine prophylaxis. Prog Neurobiol 2009;89:176-192.
17.
Ikegami A, Ozaki A, Hara H, Sukamoto T, Yamashita A, Ito K: Neurochemical investigation on the effects of a new diphenylpipirazine calcium antagonistm KB-2796, on the central dopaminergic system of rats. Jpn J Pharmacol 1992;58:399-405.
18.
Imai N, Konishi T, Serizawa M, Okabe T: Do the effects of long-term lomerizine administration differ with age? Intern Med 2007;46:683-684.
19.
Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders, ed 2. Cephalalgia 2004;24(suppl 1):9-160.
20.
Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ: New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742-746.
21.
American Psychiatric Association (APA): Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, APA Press, 1994.
22.
Chen CC, Yeh TL, Yang YK, Chen SJ, Lee IH, Fu LS, Yeh CY, Hsu HC, Tsai WL, Cheng SH, Chen LY, Si YC: Psychiatric morbidity and post-traumatic symptoms among survivors in the early stage following the 1999 earthquake in Taiwan. Psychiatry Res 2001;105:13-22.
23.
Guetti C, Angeletti C, Papola R, Petrucci E, Ursini ML, Ciccozzi A, Marinangeli F, Paladini A, Varrassi G: Headache prevalence in the population of L'Aquila (Italy) after the 2009 earthquake. J Headache Pain 2011;12:245-250.
24.
Aoki A, Aoki Y, Harima H: The impact of the Great East Japan earthquake on mandatory psychiatric emergency hospitalizations in Tokyo: a retrospective observational study. Transl Psychiatry 2012;2:e168.
25.
Tsujiuchi T, Yoshiuchi K, Shimada H, Ito K, Akabayashi A, Kumano H, Nomura S, Kuboki T, Sakano Y, Suematsu H: Psychosomatic problems after the Great Hanshin Earthquake in January 1995. II: Physical stress response (in Japanese). Jpn J Psychosom Med 1996;36:657-665.
26.
Denney DR, Frisch MB: The role of neuroticism in relation to life stress and illness. J Psychosom Res 1981;25:303-307.
27.
Bolger N, Schilling EA: Personality and the problems of everyday life: the role of neuroticism in exposure and reactivity to daily stressors. J Pers 1991;59:355-386.
28.
Breslau N, Chilcoat HD, Andreski P: Further evidence on the link between migraine and neuroticism. Neurology 1996;47:663-667.
29.
Rusting CL, Larsen RJ: Diurnal patterns of unpleasant mood: associations with neuroticism depression, and anxiety. J Pers 1998;66:85-103.
30.
Farmer A, Redman K, Harris T, Mahmood A, Sadler S, Pickering A, McGuffin P: Neuroticism, extraversion, life events and depression. The Cardiff Depression Study. Br J Psychiatry 2002;181:118-122.
31.
Kanki R, Nagaseki Y, Sakai F: Medication-overuse headache in Japan. Cephalalgia 2008;28:1227-1228.
32.
Onaya T, Ishii M, Katoh H, Shimizu S, Kasai H, Kawamura M, Kiuchi Y: Predictive index for the onset of medication overuse headache in migraine patients. Neurol Sci 2013;34:85-92.
33.
Mulder RT: Personality pathology and treatment outcome in major depression: a review. Am J Psychiatry 2002;159:359-371.
34.
Goubert L, Crombez G, Damme SV: The role of neuroticism, pain catastrophizing and pain-related fear in vigilance to pain: a structural equations approach. Pain 2004;107:234-241.
35.
Vase L, Robinson ME, Verne GN, Price DD: Increased placebo analgesia over time in irritable bowel syndrome patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 2005;115:338-347.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.